You are here: Industry Insights > EC-18

News List

FDA accepts Enzychem’s IND for trial of Covid-19 treatment candidate pharmaceutical-business-review
August 19, 2020
The US Food and Drug Administration (FDA) has accepted Enzychem Lifescience’s investigational new drug application (IND) to assess its EC-18 therapeutic candidate for the prevention of acute respiratory disease syndrome (ARDS) due to Covid-19 pneumonia.
Enzychem Files IND for Phase 2 Study of EC-18 in Preventing ARDS Due to COVID-19 Pneumonia americanpharmaceuticalreview
July 22, 2020
Enzychem Lifesciences has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of EC-18 as a preventative therapeutic against Acute Respiratory Disease Syndrome (ARDS) due to ...
Enzychem Initiates EC-18 Study to Prevent ARDS due to Coronavirus Pneumonia americanpharmaceuticalreview
May 19, 2020
Enzychem Lifesciences announced the Ministry of Food and Drug Safety (MFDS, formerly the Korea Food and Drug Administration), has accepted its Investigational New Drug (IND) application to initiate a Phase 2 study for its lead therapeutic candidate.
Enzychem Lifesciences announces filing of US provisional patent for EC-18 to treat COVID-19 pharmaceutical-business-review
April 15, 2020
Enzychem Lifesciences announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering treating COVID-19 infections and symptoms using EC-18.